Publications by authors named "Shuta Ohara"

Claim this Profile
L
Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance.
Kenichi Suda, Yukihiro Yoshida, Hidenori Sato, Shuta Ohara, Akira Hamada

Cancer Res Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current Status and Future Challenges of Liquid Biopsy.
Shuta Ohara, Kenichi Suda

Cells· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Refining Surgical Standards: The Role of Robotic-Assisted Segmentectomy in Early-Stage Non-Small-Cell Lung Cancer.
Masaya Nishino, Hideki Ujiie, Masaoki Ito, Hana Oiki, Shota Fukuda, Shuta Ohara

Cancers (Basel)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in Lung Cancer Basic and Translational Research in 2025 - Overview and Perspectives Focusing on NSCLC.
Celine Mascaux, Triparna Sen, Montse Sanchez-Cespedes, Sandra Ortiz-Cuaran, Yohan Bossé, Shuta Ohara

J Thorac Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety Profile of Neoadjuvant Chemoimmunotherapy With Nivolumab for Patients With Resectable Non-Small Cell Lung Cancer in the Real World (CReGYT-04 Neo-Venus).
Kotaro Nomura, Takuya Watanabe, Shinkichi Takamori, Akira Hamada, Kenichi Suda, Shuta Ohara, Shuichi Shinohara

Ann Thorac Surg· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon Mutations-An In Vitro Study.
Hana Oiki, Kenichi Suda, Akira Hamada, Toshio Fujino, Keiko Obata, Shuta Ohara

Cells· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility and Future Perspectives of Circulating Tumor DNA Analysis in Non-Small Cell Lung Cancer Patients in the Era of Perioperative Chemo-Immunotherapy.
Shuta Ohara, Kenichi Suda, Yasuhiro Tsutani

Cells· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Similar Trend in Benefit of Adjuvant Platinum in Lung Cancer Patients Irrespective of Epidermal Growth Factor Receptor Mutation Status.
Kenichi Suda, Kosuke Fujino, Mao Yoshikawa, Kazuhiko Shien, Ken Suzawa, Shuta Ohara

Eur J Cardiothorac Surg· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Analysis of Pathological Stage I Lung Adenocarcinoma Harboring Major EGFR Mutations.
Shinkichi Takamori, Makoto Endo, Akira Hamada, Shuta Ohara, Shota Fukuda

Clin Lung Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of PD-L1 expression in surgically resected EGFR-mutant lung adenocarcinoma: A real-world database study in Japan (CReGYT-01 EGFR study).
Kotaro Nomura, Kazuki Takada, Fumihiko Kinoshita, Satoshi Muto, Taichi Matsubara, Shuta Ohara

Int J Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Significance of Perioperative Minimal Residual Disease Detected by Circulating Tumor DNA in Patients With Lung Cancer With a Long Follow-up Data: An Exploratory Study.
Shuta Ohara, Kenichi Suda, Sumedha Sudhaman, Akira Hamada, Masato Chiba

JTO Clin Res Rep· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical factors associated with high PD-L1 expression in patients with early-stage non-small cell lung cancer.
Shuta Ohara, Kenichi Suda, Akira Hamada, Masato Chiba, Masaoki Ito

Thorac Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved platelet separation performance from whole blood using an acoustic fluidics system.
Kazuko Sakai, Shuta Ohara, Junko Tanaka, Kenichi Suda, Takamichi Muramatsu

Cancer Sci· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioinformatics analysis reveals is a prognostic factor in lung adenocarcinoma.
Ling Gao, Wei Wang, Haishan Ma, Minghui Yin, Xuejiao Yang, Shuta Ohara

Transl Cancer Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms-An In Vitro Study.
Shota Fukuda, Kenichi Suda, Akira Hamada, Hana Oiki, Shuta Ohara

Biomedicines· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation - A real-world database study in Japan: The CReGYT-01 EGFR study.
Shinya Katsumata, Mototsugu Shimokawa, Akira Hamada, Naoki Haratake, Kotaro Nomura, Shuta Ohara

Eur J Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion.
Akira Hamada, Kenichi Suda, Masaya Nishino, Keiko Obata, Hana Oiki, Shuta Ohara

J Thorac Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing.
Takamasa Koga, Junichi Soh, Akira Hamada, Yuki Miyano, Toshio Fujino, Shuta Ohara

JTO Clin Res Rep· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
Toshio Fujino, Kenichi Suda, Takamasa Koga, Akira Hamada, Shuta Ohara

J Hematol Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic Carcinomas.
Toshio Fujino, Kenichi Suda, Kazuko Sakai, Isao Murakami, Shigeki Shimizu, Shuta Ohara

Clin Lung Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC.
Akira Hamada, Kenichi Suda, Toshio Fujino, Masaya Nishino, Shuta Ohara

JTO Clin Res Rep· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequent EGFR Mutations and Better Prognosis in Positron Emission Tomography-Negative, Solid-Type Lung Cancer.
Kenichi Suda, Shuta Ohara, Toshio Fujino, Akira Hamada, Masato Chiba

Clin Lung Cancer· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial.
Akira Hamada, Kenichi Suda, Takamasa Koga, Toshio Fujino, Masaya Nishino, Shuta Ohara

Lung Cancer· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
Takamasa Koga, Kenichi Suda, Toshio Fujino, Shuta Ohara, Akira Hamada

J Thorac Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity and mechanism of acquired resistance to tarloxotinib in mutant lung cancer: an study.
Takamasa Koga, Kenichi Suda, Masaya Nishino, Toshio Fujino, Shuta Ohara

Transl Lung Cancer Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis